Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitour… Read more
Withuspharmaceutical Co.Ltd (330350) - Net Assets
Latest net assets as of September 2025: ₩98.22 Billion KRW
Based on the latest financial reports, Withuspharmaceutical Co.Ltd (330350) has net assets worth ₩98.22 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩140.92 Billion) and total liabilities (₩42.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩98.22 Billion |
| % of Total Assets | 69.7% |
| Annual Growth Rate | 11.27% |
| 5-Year Change | 21.12% |
| 10-Year Change | N/A |
| Growth Volatility | 15.09 |
Withuspharmaceutical Co.Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Withuspharmaceutical Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Withuspharmaceutical Co.Ltd (2017–2024)
The table below shows the annual net assets of Withuspharmaceutical Co.Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩93.12 Billion | +3.14% |
| 2023-12-31 | ₩90.28 Billion | +8.72% |
| 2022-12-31 | ₩83.04 Billion | +2.63% |
| 2021-12-31 | ₩80.91 Billion | +5.24% |
| 2020-12-31 | ₩76.88 Billion | +0.15% |
| 2019-12-31 | ₩76.76 Billion | +46.41% |
| 2018-12-31 | ₩52.43 Billion | +18.90% |
| 2017-12-31 | ₩44.10 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Withuspharmaceutical Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 75.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩74.73 Billion | 80.26% |
| Common Stock | ₩2.64 Billion | 2.84% |
| Other Components | ₩15.74 Billion | 16.91% |
| Total Equity | ₩93.12 Billion | 100.00% |
Withuspharmaceutical Co.Ltd Competitors by Market Cap
The table below lists competitors of Withuspharmaceutical Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hong Ho Precision Textile Co Ltd
TW:1446
|
$34.74 Million |
|
Birikim Varlik Yonetim A.S.
IS:BRKVY
|
$34.74 Million |
|
Master Tec Group Berhad
KLSE:0295
|
$34.75 Million |
|
Mcleod Russel India Limited
NSE:MCLEODRUSS
|
$34.75 Million |
|
BATI EGE GMYO
IS:BEGYO
|
$34.72 Million |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
$34.69 Million |
|
LEBON NOM. O.N.
F:88J
|
$34.67 Million |
|
Sensys Gatso Group AB
ST:SGG
|
$34.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Withuspharmaceutical Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 90,277,966,700 to 93,116,677,060, a change of 2,838,710,360 (3.1%).
- Net income of 4,784,739,820 contributed positively to equity growth.
- Dividend payments of 1,319,031,900 reduced retained earnings.
- Share repurchases of 806,310 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.78 Billion | +5.14% |
| Dividends Paid | ₩1.32 Billion | -1.42% |
| Share Repurchases | ₩806.31K | -0.0% |
| Other Changes | ₩-626.19 Million | -0.67% |
| Total Change | ₩- | 3.14% |
Book Value vs Market Value Analysis
This analysis compares Withuspharmaceutical Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.20x to 1.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩3793.24 | ₩8330.00 | x |
| 2018-12-31 | ₩4510.03 | ₩8330.00 | x |
| 2019-12-31 | ₩5820.16 | ₩8330.00 | x |
| 2020-12-31 | ₩5829.07 | ₩8330.00 | x |
| 2021-12-31 | ₩6135.62 | ₩8330.00 | x |
| 2022-12-31 | ₩6295.23 | ₩8330.00 | x |
| 2023-12-31 | ₩6844.26 | ₩8330.00 | x |
| 2024-12-31 | ₩7054.46 | ₩8330.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Withuspharmaceutical Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.14%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.66%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.45x
- Recent ROE (5.14%) is below the historical average (8.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 19.26% | 16.67% | 0.74x | 1.57x | ₩4.08 Billion |
| 2018 | 16.52% | 16.74% | 0.68x | 1.45x | ₩3.42 Billion |
| 2019 | 10.47% | 15.34% | 0.49x | 1.39x | ₩362.65 Million |
| 2020 | 2.43% | 7.12% | 0.25x | 1.38x | ₩-5.82 Billion |
| 2021 | 5.27% | 7.43% | 0.48x | 1.47x | ₩-3.83 Billion |
| 2022 | 2.99% | 3.83% | 0.54x | 1.44x | ₩-5.82 Billion |
| 2023 | 8.82% | 9.93% | 0.61x | 1.45x | ₩-1.07 Billion |
| 2024 | 5.14% | 4.66% | 0.76x | 1.45x | ₩-4.53 Billion |
Industry Comparison
This section compares Withuspharmaceutical Co.Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Withuspharmaceutical Co.Ltd (330350) | ₩98.22 Billion | 19.26% | 0.43x | $34.73 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |